About Omnicell

About Us

Letter to Our Customers About the Aesynt Acquisition

I am excited to let you know that the completion of the Aesynt acquisition was announced January 6, 2016. As a result, Omnicell is now uniquely positioned to offer customers an unprecedented choice of medication management technology, including central pharmacy, point-of-care, IV compounding, medication adherence solutions, and a growing capability in analytics.

We believe customers will experience significant benefits from the combination of our two teams. For example, integrating our product development groups is expected to lead to some exciting breakthroughs and the opportunity to accelerate innovation in our industry.

At present, there will be no changes to your current contacts in the field organization such as sales representatives, service technicians, or technical support representatives. Our highest priority is customer satisfaction, and we do not intend to make any changes that would adversely affect customers.   

I am excited about the strong potential of the combined entity, and I hope you share our enthusiasm as we continue our commitment to improve health care for everyone. Our press release provides additional details on the acquisition.

If you have any questions, please feel free to contact me.

Yours sincerely,
 Randall Lipps

Randall A. Lipps
Chairman, President, CEO and Founder
Omnicell, Inc.

Founded From the Heart

When his daughter was hospitalized at birth, Randall Lipps observed much inefficiency in the way hospital supplies were managed, and he saw that it prevented nursing staff from spending more time directly caring for patients. He founded Omnicell, Inc. in 1992 on the premise that better management of supplies and medications would improve a hospital’s standard of care by allowing clinicians to spend more time with their patients.

Mr. Lipps has served as Omnicell’s Chairman since the company’s founding, and in 2002 he assumed the additional position of President and Chief Executive Officer, taking a more active leadership role in the company’s operations. 

Omnicell, Inc. Today

Omnicell is recognized as a leading provider of comprehensive, technologically advanced automation that enables health care facilities to acquire, manage, dispense, and deliver medications and supplies more effectively. Omnicell automation is used from the point of entry into the hospital through the central pharmacy, nursing units, operating room, procedural areas, and patient bedsides – as well as in long-term care sites.

For over 20 years the mission of Omnicell has focused on improving the medication and supply distribution process. More than 4,000 acute care customers worldwide have used Omnicell’s medication automation, supply chain, and analytics solutions to improve efficiency, reduce errors, and lower costs.

Omnicell non-acute care solutions, including the MTS brand, enable approximately 7,000 institutional and retail pharmacies worldwide to optimize productivity and control costs. Moreover, the innovative medication adherence packaging solutions can reduce costly hospital readmissions.

At Omnicell, delivering our technology is just the beginning. We are also committed to delivering the best customer experience. To ensure our customers gain the most utility from their Omnicell systems, we offer a suite of analytics software, a comprehensive training and education program, and first-rate customer support. Omnicell has been recognized with a KLAS award every year since 2006.

Key product lines:

  • Pharmacy automation, including robotic systems
  • IV compounding automation and services
  • Medication dispensing systems
  • Supply dispensing systems
  • Inventory management and drug diversion analytics
  • Medication adherence solutions

For more information about Omnicell products and services, please explore our website, or contact us directly.